Whooping Cough: all 290 studies

Page 2 of 3. Open to participants first (23), then studies with results posted, then the rest; newest registration first within each.

• Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPVCompletedNCT00362336Phase 3Results posted
• Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®CompletedNCT00355121Phase 2Results posted
• Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy InfantsCompletedNCT00348881Phase 3Results posted
• Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® VaccineCompletedNCT00347958Phase 4Results posted
• Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 YearsCompletedNCT00346073Phase 3Results posted
• Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio VaccineCompletedNCT00343889Phase 3Results posted
• Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)CompletedNCT00337428Phase 3Results posted
• Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)CompletedNCT00325130Phase 3Results posted
• Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®CompletedNCT00319553Phase 4Results posted
• Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed SubjectsCompletedNCT00317109Phase 3Results posted
• Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months ScheduleCompletedNCT00315055Phase 3Results posted
• Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.CompletedNCT00313911Phase 3Results posted
• Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis VaccineCompletedNCT00304265Phase 4Results posted
• Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean InfantsCompletedNCT00303316Phase 3Results posted
• Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 StudyCompletedNCT00291343Phase 3Results posted
• US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal DiseaseCompletedNCT00282295Phase 4Results posted
• Immunogenicity and Safety of ADACEL™ as Fifth Dose in TaiwanCompletedNCT00258908Phase 3Results posted
• Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®CompletedNCT00258895Phase 3Results posted
• Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ VaccineCompletedNCT00258882Results posted
• Safety and Immune Response of Different Pediatric Combination Vaccines.CompletedNCT00255047Phase 3Results posted
• Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to InfantsCompletedNCT00158756Phase 3Results posted
• A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged 11 Years to <13 YearsCompletedNCT07596173Phase 3
• Safety Monitoring of Boostagen® Vaccine in ThailandCompletedNCT07444502
• Safety Monitoring of VacPertagen Vaccine in ThailandCompletedNCT07400120
• Immunogenicity of a Combined Diphtheria-Tetanus-recombinant Acellular Pertussis (DTaP) Vaccine in Healthy ToddlersCompletedNCT07213089Phase 2/3
• A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary SeriesActive, not recruitingNCT06947499Phase 2/3
• A Phase 4, Randomised Vaccination Study in Healthy Adults to Investigate the Effects of Acellular Pertussis Vaccine on Colonisation With Bordetella Pertussis Using Controlled Human InfectionActive, not recruitingNCT06903221Phase 4
• Study Evaluating the Safety of a Recombinant Acellular Pertussis Vaccine in Pregnant WomenActive, not recruitingNCT06888076
• 10-year Follow-up After a Single Dose Acellular Pertussis VaccinationCompletedNCT06803524Phase 4
• Study Evaluating the Safety of a Recombinant Acellular Pertussis Vaccine in AdultsActive, not recruitingNCT06798831Phase 3
• A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)CompletedNCT06708286Phase 2/3
• CARE-ID: Dynamics of Respiratory Infections in Children and Transmission in Households and SchoolsActive, not recruitingNCT06640387
• Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPVCompletedNCT06413121Phase 3
• LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in AustraliaStatus unknownNCT06392451Not applicable
• Safety of Tetanus, Diphtheria, Acellular Pertussis With 5 Acellular Pertussis Components (Tdap5) Vaccination During PregnancyActive, not recruitingNCT06258057
• A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)CompletedNCT06056050Phase 1
• Maternal Determinants of Infant Immunity to PertussisCompletedNCT05856396Phase 4
• Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary SeriesCompletedNCT05457946Phase 2/3
• Pertussis Vaccination Among HIV-infected and HIV-uninfected Pregnant WomenCompletedNCT05264662Phase 4
• Influenza and Pertussis Vaccination Status of Women in Immediate Postpartum and CaregiversCompletedNCT05234229
• Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-detoxified Pertussis Toxin in Young Adults Previously Primed With Acellular Pertussis VaccinesStatus unknownNCT05193734Phase 2/3
• A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, AdsorbedActive, not recruitingNCT05091619Phase 3
• Effectiveness of Adacel Vaccination in Pregnancy at Preventing Pertussis in Infants < 2 Months of Age in the United StatesCompletedNCT05040802
• Pertussis Acellular Vaccine Adjuvanted With TQL1055TerminatedNCT04793620Phase 1
• Seroprevalence of Pertussis Among Healthy Children and Adolescents in KazakhstanStatus unknownNCT04779853
• A Multi-center Study to Determine the Prevalence and Influence of Pertussis on Subacute Cough in ShenzhenStatus unknownNCT04694963
• A Multi-center Study to Determine the Prevalence and Influence of Pertussis on COPD Exacerbation in ShenzhenStatus unknownNCT04694430
• Assessment, Feedback, Incentive, Exchange (AFIX OB) A Customizable Quality Improvement Intervention to Increase Maternal Vaccine UptakeCompletedNCT04678271Not applicable
• To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 YearsStatus unknownNCT04618640Phase 3
• Maternal Pertussis Wholecell ResponsesCompletedNCT04589312Phase 2
• Adacel® Booster Vaccination for CMI Assay DevelopmentCompletedNCT04543669Phase 4
• Pathogenic Bordetella Rapid DetectionWithdrawnNCT04535505
• 5-year Follow-up After a Single Dose Acellular Pertussis VaccinationCompletedNCT04529720
• Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in ThailandCompletedNCT04429295Phase 3
• Adapting Motivational Interviewing for Maternal Immunizations (MI4MI)CompletedNCT04302675Not applicable
• Study to Evaluate the Immune Response After Booster Vaccination With Tdap-IPV Vaccine (Against Tetanus, Diphtheria, Pertussis and Poliomyelitis) in Children Who Received Different Pertussis Primary Vaccine Regimens in Republic of South AfricaCompletedNCT04300192Phase 4
• A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy AdultsStatus unknownNCT04238975Phase 2
• Evaluating a Caregiver SMS Reminder Intervention to Reduce Immunization Drop-out in Arua, UgandaCompletedNCT04177485Not applicable
• 2-year Follow-up After a Single Dose Acellular Pertussis VaccinationCompletedNCT04113655
• 3-year Follow-up After a Single Dose Acellular Pertussis VaccinationCompletedNCT04102137
• Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed .CompletedNCT04099303Phase 1
• Immune Response followingTdap Vaccine in PregnancyCompletedNCT04082299
• Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy InfantsStatus unknownNCT04073459Phase 2
• A Phase IV Study to Assess the Safety of EupentaTM InjStatus unknownNCT04056728Phase 4
• A Phase 1/2 Clinical Trial of a GamLPV, a Live Intranasal Bordetella Pertussis VaccineStatus unknownNCT04036526Phase 1/2
• Sources of COmplement in Meningococcal and Pertussis Serum Bactericidal Antibody AssaysStatus unknownNCT04023929
• Maternal Antibody in Milk After VaccinationStatus unknownNCT03982732
• A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in CanadaCompletedNCT03958799Phase 1
• Increasing Vaccine Uptake Among Veterans at the Atlanta VA Health Care SystemCompletedNCT03950986Not applicable
• The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 WeeksCompletedNCT03931239Not applicable
• Pertussis Vaccination in Pregnant WomenCompletedNCT03909126Phase 4
• Optimising the Timing of Whooping Cough Immunisation in MUMsStatus unknownNCT03908164Phase 4
• Evaluation of an Infant Immunization Encouragement Program in NigeriaCompletedNCT03870061Not applicable
• Bordetella Pertussis Colonisation Challenge StudyStatus unknownNCT03751514Not applicable
• A Study Exploring Whooping Cough Protection in Children and AdultsCompletedNCT03697798Phase 4
• Gambia Pertussis Study (GaPs)Status unknownNCT03606096Phase 4
• Immunising Mums Against Pertussis 3CompletedNCT03578120
• Pertussis Immunization During Pregnancy & HIV InfectionCompletedNCT03519373
• Optimising Protection for Pregnant Women and Infants With Maternal VaccinationActive, not recruitingNCT03457194
• Pertussis Immunization Programs in Low Income Countries - Ivory CoastCompletedNCT03388034
• Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in PakistanStatus unknownNCT03341195Not applicable
• The Feasibility of Pertussis Immunization in a Canadian Emergency DepartmentCompletedNCT03304275Not applicable
• A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy AdultsCompletedNCT03208101Phase 1
• EUpertstrain 4 Study of Bordetella Pertussis IsolatesCompletedNCT03197597
• Immunogenicity of a Single Dose of GSK Biologicals' Boostrix™ in Infants Prior to Primary Pertussis Vaccination, When Administered to Pregnant Women as Per Routine Practice in Bogota, ColombiaTerminatedNCT03188458Phase 4
• Observational Study Describing the Immune Profile Induced By Pertussis VaccinesCompletedNCT03147898
• A Phase I Clinical Study of a GamLPV, a Live Intranasal Bordetella Pertussis VaccineCompletedNCT03137927Phase 1
• CD8 Reactivity to Microorganisms in Blood and Breast MilkTerminatedNCT03084614
• Viaskin Pertussis Vaccine TrialCompletedNCT03035370Phase 1
• Pertussis Immunization Programs in Low Income CountriesCompletedNCT02983487
• The PertADO Geneva TrialCompletedNCT02946190Phase 2
• A Multi-Site Clinical Evaluation of the ARIES Bordetella Assay in Symptomatic PatientsCompletedNCT02862262Not applicable
• DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected InfantsCompletedNCT02817451Phase 3
• Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) VaccineStatus unknownNCT02813486Phase 1/2
• Influence of BCG on TDaP-IPV VaccinationStatus unknownNCT02771782Phase 4
• Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia.CompletedNCT02569879
• Placebo Controlled Study to Generate Data Characterising Safety Parameters and Immune ResponsesCompletedNCT02555540Phase 4
• Pertussis and Meningitis C Concomitant Vaccination in AdolescentsCompletedNCT02526394Phase 4
• Pertussis Immunization During Pregnancy: Effect in Term and Preterm InfantsStatus unknownNCT02511327
• Study of Adsorption Tetanus-diphtheria-acellular Pertussis (DTaP) Vaccine in Healthy 3 to 5 Months InfantsCompletedNCT02477995Phase 3

← Whooping Cough overview